Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
Status:
Withdrawn
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and
tolerability of MAA868 compared to apixaban in patients with atrial fibrillation.